North America Cardiac Disease Market Outlook to 2036 – Cardiac Marker Tests

All the vital news, analysis, and commentary curated by our industry experts.

$5995

Buy Report

Published: May 30, 2026 Report Code: GDME22058CRDB-ST

Report Overview
Key Players
Table of Contents
Table
Figures

GlobalData’s “North America Cardiac Disease Market Outlook to 2036” is a comprehensive databook report, covering key market data on the North America Cardiac Disease market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Cardiac Marker Tests

The North America Cardiac Disease Market report provides key information and data on –
– Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments. Data is provided from 2024 to 2036.
– 2025 company share data for Cardiac Disease Market.
– Global corporate-level profiles of key companies operating within the North America Cardiac Disease Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.

Scope

North America Cardiac Disease is segmented as follows:

– Cardiac Marker Tests

Reasons to Buy

The North America Cardiac Disease Market report helps you to develop:

– Business strategies by identifying the key market segments poised for strong growth in the future.

– Market-entry and market expansion strategies.

– Design competition strategies by identifying who-stands-where in the market.

– Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.

F. Hoffmann-La Roche Ltd
Abbott Laboratories
Beckman Coulter Inc
Quidel Corp
Siemens Healthineers AG
bioMerieux SA

Table of Contents_x000D_

List of Tables_x000D_

List of Figures_x000D_

1 Introduction_x000D_

1.1 What Is This Report About?_x000D_

1.2 Cardiac Disease Market Segmentation_x000D_

1.3 Definitions of Markets Covered in the Report_x000D_

2 Cardiac Disease Market, North America_x000D_

2.1 Cardiac Disease Market, North America, Revenue ($m), 2024-2036_x000D_

2.2 Cardiac Disease Market, North America, Revenue ($m), 2024-2036_x000D_

2.3 Cardiac Disease Market, North America, Volume (Units), 2024-2036_x000D_

2.4 Cardiac Disease Market, North America, Volume (Units), 2024-2036_x000D_

2.5 Cardiac Disease Market, North America, Company Share by Revenue ($m), 2025_x000D_

3 Cardiac Disease Market, Canada_x000D_

3.1 Cardiac Disease Market, Canada, Revenue ($m), 2024-2036_x000D_

3.1.1 Cardiac Marker Tests Market, Canada, Revenue ($m), by Segment, 2024-2036_x000D_

3.2 Cardiac Disease Market, Canada, Volume (Units), 2024-2036_x000D_

3.2.1 Cardiac Marker Tests Market, Canada, Volume (Units), by Segment, 2024-2036_x000D_

3.3 Cardiac Disease Market, Canada, Average Price ($), 2024-2036_x000D_

3.4 Cardiac Disease Market, Canada, Company Share by Revenue ($m), 2025_x000D_

4 Cardiac Disease Market, Mexico_x000D_

4.1 Cardiac Disease Market, Mexico, Revenue ($m), 2024-2036_x000D_

4.1.1 Cardiac Marker Tests Market, Mexico, Revenue ($m), by Segment, 2024-2036_x000D_

4.2 Cardiac Disease Market, Mexico, Volume (Units), 2024-2036_x000D_

4.2.1 Cardiac Marker Tests Market, Mexico, Volume (Units), by Segment, 2024-2036_x000D_

4.3 Cardiac Disease Market, Mexico, Average Price ($), 2024-2036_x000D_

4.4 Cardiac Disease Market, Mexico, Company Share by Revenue ($m), 2025_x000D_

5 Cardiac Disease Market, United States_x000D_

5.1 Cardiac Disease Market, United States, Revenue ($m), 2024-2036_x000D_

5.1.1 Cardiac Marker Tests Market, United States, Revenue ($m), by Segment, 2024-2036_x000D_

5.2 Cardiac Disease Market, United States, Volume (Units), 2024-2036_x000D_

5.2.1 Cardiac Marker Tests Market, United States, Volume (Units), by Segment, 2024-2036_x000D_

5.3 Cardiac Disease Market, United States, Average Price ($), 2024-2036_x000D_

5.4 Cardiac Disease Market, United States, Company Share by Revenue ($m), 2025_x000D_

6 Cardiac Disease Market Pipeline Products_x000D_

6.1 Cardiac Disease Market Pipeline Products_x000D_

6.2 Cardiac Disease – Pipeline Products by Stage of Development_x000D_

6.3 Cardiac Disease – Pipeline Products by Segment_x000D_

6.4 Cardiac Disease – Pipeline Products by Territory_x000D_

6.5 Cardiac Disease – Pipeline Products by Regulatory Path_x000D_

6.6 Cardiac Disease – Pipeline Products by Estimated Approval Date_x000D_

7 Overview of Key Companies in North America Cardiac Disease Market_x000D_

7.1 F. Hoffmann-La Roche Ltd_x000D_

7.1.1 Company Overview_x000D_

7.2 Abbott Laboratories_x000D_

7.2.1 Company Overview_x000D_

7.3 Beckman Coulter Inc_x000D_

7.3.1 Company Overview_x000D_

7.4 Quidel Corp_x000D_

7.4.1 Company Overview_x000D_

7.5 Siemens Healthineers AG_x000D_

7.5.1 Company Overview_x000D_

7.6 bioMerieux SA_x000D_

7.6.1 Company Overview_x000D_

8 Recent Developments_x000D_

8.1 Corporate Communications_x000D_

8.1.1 Feb 09, 2026: Humacyte Announces New u.s. Department of Defense Funding for Procurement of Bioengineered Blood Vessels_x000D_

8.1.2 Jan 27, 2026: Johnson & Johnson Marks $100 Million of Medtech Products Donated Since 2020 To Help People Live, See and Smile_x000D_

8.1.3 Oct 02, 2025: Dyne Therapeutics Appoints Brian Posner to Its Board of Directors_x000D_

8.2 Financial Announcements_x000D_

8.2.1 Apr 15, 2026: Cosmos Health Reports Full Year 2025 Results_x000D_

8.2.2 Feb 18, 2026: Cardio Diagnostics Holdings to Host Investor Call on Thursday, February 19, 2026_x000D_

8.3 Government and Public Interest_x000D_

8.3.1 Nov 03, 2025: Dyne Therapeutics to Present at Upcoming Investor Conferences_x000D_

8.4 Legal And Regulatory_x000D_

8.4.1 Sep 02, 2025: Innovative Health Prevails in Lawsuit Against J&J's Biosense Webster for Restraint of Trade_x000D_

8.5 Other Significant Developments_x000D_

8.5.1 Feb 18, 2026: Maestro MEA Platform Powers First Stem Cell Cardiac Safety Assay in FDA ISTAND Program_x000D_

8.5.2 Nov 24, 2025: AI/ML Subsidiary Neural Cloud Begins Pilot at SickKids to Advance AI-Enabled Pediatric Cardiac Care_x000D_

8.6 Product News_x000D_

8.6.1 May 11, 2026: Heart scan and blood test improve risk prediction for inherited heart condition, major study finds_x000D_

8.6.2 Apr 30, 2026: Medical Component Specialists to Support Catheter R&D Masterclass in Ireland_x000D_

8.6.3 Mar 12, 2026: PsyMetRiC: Tool to Predict Physical Health Risks in Young People With Psychosis_x000D_

8.6.4 Mar 10, 2026: New AI Solution Helps Predict Which Lung Cancer Patients Will Benefit from Immunotherapy_x000D_

8.6.5 Feb 12, 2026: HRS Releases Scientific Statement on Pulsed Field Ablation for Cardiac Arrhythmias_x000D_

8.6.6 Oct 27, 2025: University of Alberta : Some Cancer Patients Get Heart Damage During Chemotherapy and Some Don’t_x000D_

8.6.7 Oct 21, 2025: PET Imaging of Inflammation Predicts Recovery, Guides Therapy After Heart Attack_x000D_

8.6.8 Oct 06, 2025: New Calculator to Better Predict Stroke Risk in Atrial Fibrillation Patients_x000D_

8.6.9 Sep 17, 2025: AI Outperforms Doctors In Predicting Surgical Complications_x000D_

8.6.10 Aug 28, 2025: Esaote Group to Showcase Cardiac Innovation at ESC 2025 in Madrid_x000D_

8.6.11 Jun 09, 2025: Microtech Announces the First U.S. Atrial Microsensor Implantations as Part of Its FIH Study_x000D_

8.6.12 Jun 09, 2025: Phillips Medisize Launches Theravolt Medical Connectors To Support Next-Gen Device Integration, Connectivity and Performance_x000D_

8.7 Strategy And Business Planning_x000D_

8.7.1 Feb 17, 2026: McLaren Health Care Launches AI-Powered Cardiovascular Screening in Michigan_x000D_

8.7.2 Feb 06, 2026: Mercedes Medical : Introducing Our Expanded Warehouse Network_x000D_

8.7.3 Jan 20, 2026: Foxo Technologies Subsidiary, Big South Fork Medical Center, Expands Clinical Capabilities_x000D_

8.7.4 Jul 17, 2025: Catalyst Medtech Announces Expansion of Strategic Partnership With Arineta_x000D_

8.7.5 Jul 07, 2025: Lifeforce and Toku Announce Nationwide Partnership_x000D_

9 Appendix_x000D_

9.1 Research Methodology_x000D_

9.1.1 Coverage_x000D_

9.1.2 Secondary Research_x000D_

9.1.3 Primary Research_x000D_

9.1.4 Market Modeling and Forecasting_x000D_

9.1.5 Company Share Analysis_x000D_

9.1.6 Benchmarking_x000D_

9.2 GlobalData Consulting_x000D_

9.3 Contact Us_x000D_

9.4 Disclaimer

Table

Table 1: Cardiac Disease Market, Cross Country Comparison, North America, Revenue ($m), USD Constant, 2024-2036

Table 2: Cardiac Disease Market, North America, Revenue ($m), USD Constant, 2024-2036

Table 3: Cardiac Disease Market, North America, Volume (Units), 2024-2036

Table 4: Cardiac Disease Market, North America, Volume (Units), 2024-2036

Table 5: Cardiac Disease Market, North America, Company Share by Revenue ($m), 2025

Table 6: Cardiac Disease Market, Canada, Revenue ($m), USD Constant, 2024-2036

Table 7: Cardiac Marker Tests Market, Canada, Revenue ($m), USD Constant, 2024-2036

Table 8: Cardiac Disease Market, Canada, Volume (Units), 2024-2036

Table 9: Cardiac Marker Tests Market, Canada, Volume (Units), 2024-2036

Table 10: Cardiac Disease Market, Canada, Average Price ($), 2024-2036

Table 11: Cardiac Disease Market, Canada, Company Share by Revenue ($m), USD Constant, 2025

Table 12: Cardiac Disease Market, Mexico, Revenue ($m), USD Constant, 2024-2036

Table 13: Cardiac Marker Tests Market, Mexico, Revenue ($m), USD Constant, 2024-2036

Table 14: Cardiac Disease Market, Mexico, Volume (Units), 2024-2036

Table 15: Cardiac Marker Tests Market, Mexico, Volume (Units), 2024-2036

Table 16: Cardiac Disease Market, Mexico, Average Price ($), 2024-2036

Table 17: Cardiac Disease Market, Mexico, Company Share by Revenue ($m), USD Constant, 2025

Table 18: Cardiac Disease Market, United States, Revenue ($m), USD Constant, 2024-2036

Table 19: Cardiac Marker Tests Market, United States, Revenue ($m), USD Constant, 2024-2036

Table 20: Cardiac Disease Market, United States, Volume (Units), 2024-2036

Table 21: Cardiac Marker Tests Market, United States, Volume (Units), 2024-2036

Table 22: Cardiac Disease Market, United States, Average Price ($), 2024-2036

Table 23: Cardiac Disease Market, United States, Company Share by Revenue ($m), USD Constant, 2025

Table 24: Cardiac Disease Market Pipeline Products

Table 25: Cardiac Disease – Pipeline Products by Stage of Development

Table 26: Cardiac Disease Companies – Pipeline Products by Stage of Development

Table 27: Cardiac Disease – Pipeline Products by Segment

Table 28: Cardiac Disease – Pipeline Products by Territory

Table 29: Cardiac Disease – Pipeline Products by Regulatory Path

Table 30: Cardiac Disease – Pipeline Products by Estimated Approval Date

Table 31: Total Number of Primary Research Participants, In Vitro Diagnostics Market, by Country

Figures

Figure 1: Cardiac Disease Market, Cross Country Comparison, North America, Revenue ($m), USD Constant, 2024-2036

Figure 2: Cardiac Disease Market, North America, Revenue ($m), USD Constant, 2024-2036

Figure 3: Cardiac Disease Market, North America, Volume (Units), 2024-2036

Figure 4: Cardiac Disease Market, North America, Volume (Units), 2024-2036

Figure 5: Cardiac Disease Market, North America, Company Share (%), 2025

Figure 6: Cardiac Disease Market, Canada, Revenue ($m), USD Constant, 2024-2036

Figure 7: Cardiac Marker Tests Market, Canada, Revenue ($m), USD Constant, 2024-2036

Figure 8: Cardiac Disease Market, Canada, Volume (Units), 2024-2036

Figure 9: Cardiac Marker Tests Market, Canada, Volume (Units), 2024-2036

Figure 10: Cardiac Disease Market, Canada, Company Share (%), 2025

Figure 11: Cardiac Disease Market, Mexico, Revenue ($m), USD Constant, 2024-2036

Figure 12: Cardiac Marker Tests Market, Mexico, Revenue ($m), USD Constant, 2024-2036

Figure 13: Cardiac Disease Market, Mexico, Volume (Units), 2024-2036

Figure 14: Cardiac Marker Tests Market, Mexico, Volume (Units), 2024-2036

Figure 15: Cardiac Disease Market, Mexico, Company Share (%), 2025

Figure 16: Cardiac Disease Market, United States, Revenue ($m), USD Constant, 2024-2036

Figure 17: Cardiac Marker Tests Market, United States, Revenue ($m), USD Constant, 2024-2036

Figure 18: Cardiac Disease Market, United States, Volume (Units), 2024-2036

Figure 19: Cardiac Marker Tests Market, United States, Volume (Units), 2024-2036

Figure 20: Cardiac Disease Market, United States, Company Share (%), 2025

Figure 21: Cardiac Disease – Pipeline Products by Stage of Development

Figure 22: Cardiac Disease – Pipeline Products by Segment

Figure 23: Cardiac Disease – Pipeline Products by Territory

Figure 24: Cardiac Disease – Pipeline Products by Regulatory Path

Figure 25: Cardiac Disease – Pipeline Products by Estimated Approval Date

North America Cardiac Disease Market Outlook to 2036 – Cardiac Marker Tests standard reports

Currency USD

Single User

$5,995

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more In Vitro Diagnostics reports

Medical Devices

New

Medical Devices M&A Deals H1 2026 - Top Themes: Strategic…

Medical Devices

New

AI-designed Materials: Market Trends and Innovations

Medical Devices

New

Dental Implants and Abutments Market Size by Segments, Share, Regulatory,…

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at North America Cardiac Disease Market Outlook to 2036 – Cardiac Marker Tests in real time.

Access a live North America Cardiac Disease Market Outlook to 2036 – Cardiac Marker Tests dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

North America Cardiac Disease Market Outlook to 2036 – Cardiac Marker Tests

Scope

Reasons to Buy

Table of Contents

Table

Figures

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Related reports